Skip to main content

Table 1 Comparison of baseline data between warfarin and rivaroxaban groups

From: Rivaroxaban versus warfarin for the management of left ventricle thrombus

  Warfarin (n= 35) Rivaroxaban (n= 28) p
Age (years) 59 (15.62) 58.25 (17.73) 0.86
Male 34 (97.14%) 24 (85.71%) 0.16
BMI (kg/m2) 28.1 (4.04) 27.59 (5.88) 0.69
BSA (m2) 1.91 (0.16) 1.87 (0.25) 0.51
Diabetes mellitus 16 (45.71%) 12 (42.86%) 0.82
Hypertension 19 (54.29%) 13 (46.43%) 0.54
Atrial fibrillation 2 (5.71%) 1 (3.57%) ˃ 0.99
Myocardial infarction 25 (71.43%) 16 (57.14%) 0.24
Hemoglobin (g/dl) 14.1 (1.91) 13.4 (2.25) 0.19
Creatinine clearance (ml/min) 80.6 (38.66) 92.28 (32.37) 0.21
ALT (U/L) 21 (17-34) 31 (18-43) 0.10
ALP (U/L) 90 (70-108) 86 (72-115) 0.97
Aspirin 20 (57.14%) 19 (67.86%) 0.38
P2Y12 inhibitors (clopidogrel) 21 (60%) 13 (46.43%) 0.24
Ejection fraction (%) 27.29 (7.8) 26.43 (8.15) 0.67
LVT surface area (cm2) 1.77 (0.66-2.21) 1.75 (0.7-3.49) 0.3
Moderate MR 5 (14.3%) 7 (25%) 0.28
Moderate TR 3 (8.6%) 5 (17.9%) 0.45
Dilated LV 9 (25.71%) 14 (50%) 0.047
INR base 1.2 (1.1-2.2) 1.2 (1.1-1.6) 0.92
  1. ALP alkaline phosphatase, ALT alanine transaminase, BMI body mass index, BSA body surface area, INR international normalization ratio, LVT left ventricular thrombus, MR mitral regurgitation, TR tricuspid regurgitation
  2. Continuous data are presented as mean (standard deviation) if normally distributed and median (Q1-Q3) if non-normally distributed and categorical data as number (%)
  3. Patients on aspirin or P2Y12 inhibitors had these medications on admission and continued during warfarin or rivaroxaban therapy
  4. Aspirin dose was 81 mg/day; clopidogrel dose was 75 mg/day